Skip to main content

ActivX Biosciences, Kyorin Pharmaceutical To Develop Diabetes Drugs

NEW YORK, June 4-ActivX Biosciences has inked a deal with Tokyo's Kyorin Pharmaceutical company to identify and optimize new drugs for type II diabetes, the company said today.

 

ActivX, which studies protein activity in disease, will develop assays, screen and profile hit and lead compounds. Kyorin will provide the company with research support, milestone payments, and royalties on any commercialized products. ActivX also retains rights for some compounds that may be active in other diseases.

 

Kyorin will conduct medicinal chemistry, animal pharmacology and clinical development on lead compounds. The company has worldwide manufacturing and marketing rights to any drugs developed in the collaboration.

 

ActivX is the Japanese pharmaceutical company's first U.S. biotechnology partner.

 

Based in La Jolla, ActivX studies disease mechanisms by analyzing protein activity.

 

For further details, read the press release.

The Scan

Possibly as Transmissible

Officials in the UK say the B.1.617.2 variant of SARS-CoV-2 may be as transmitted as easily as the B.1.1.7 variant that was identified in the UK, New Scientist reports.

Gene Therapy for SCID 'Encouraging'

The Associated Press reports that a gene therapy appears to be effective in treating severe combined immunodeficiency syndrome.

To Watch the Variants

Scientists told US lawmakers that SARS-CoV-2 variants need to be better monitored, the New York Times reports.

Nature Papers Present Nautilus Genome, Tool to Analyze Single-Cell Data, More

In Nature this week: nautilus genome gives peek into its evolution, computational tool to analyze single-cell ATAC-seq data, and more.